Linked Life Data

18977269

Source:http://linkedlifedata.com/resource/pubmed/id/18977269

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-12-2
pubmed:abstractText
The potent IFN-gamma inducing fusion antigen Ag85B-ESAT-6 (85B6) is a lead subunit candidate to improve current vaccination against Mycobacterium tuberculosis (Mtb). The recombinant M. bovis BCG strain Myc3504 was constructed to secrete 85B6. It was based on commercial BCG strain Moreau Rio de Janeiro (BCG(MoWT)) which remains available for human oral administration. Myc 3504 induced higher levels of 85B6-specific IFN-gamma circulating T-cells as compared to BCG(MoWT). A novel needle-free mucosal immunization regimen combining oral prime with Myc3504 or BCG(MoWT) with intranasal boost with LTK-63-adjuvanted 85B6 was compared to subcutaneous prime-boost immunization. Strikingly whereas parenteral immunization induced sustained levels of 85B6-specific IFN-gamma secretion by circulating T-cells, mucosal regimens induced barely detectable IFN-gamma. Despite this, mice and guinea pigs immunized with the mucosal regimens were as efficiently protected against aerosol Mtb challenge as parenterally immunized animals. After Mtb challenge, anti-ESAT-6 IFN-gamma responses sharply increased in non-vaccinated mice as a hallmark of infection. Parenterally immunized mice that controlled Mtb infection, displayed anti-ESAT-6 IFN-gamma responses as high as non-immunized infected mice, compromising the possible use of ESAT-6 as a diagnostic tool. Interestingly, in mucosally immunized mice that were equally protected, post-challenge ESAT-6-specific IFN-gamma T-cell response remained low.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
28-37
pubmed:meshHeading
pubmed-meshheading:18977269-Acyltransferases, pubmed-meshheading:18977269-Administration, Intranasal, pubmed-meshheading:18977269-Animals, pubmed-meshheading:18977269-Antigens, Bacterial, pubmed-meshheading:18977269-BCG Vaccine, pubmed-meshheading:18977269-Bacterial Proteins, pubmed-meshheading:18977269-Female, pubmed-meshheading:18977269-Guinea Pigs, pubmed-meshheading:18977269-Humans, pubmed-meshheading:18977269-Immunization, Secondary, pubmed-meshheading:18977269-Interferon-gamma, pubmed-meshheading:18977269-Mice, pubmed-meshheading:18977269-Mice, Inbred BALB C, pubmed-meshheading:18977269-Mice, Inbred C57BL, pubmed-meshheading:18977269-Mycobacterium bovis, pubmed-meshheading:18977269-Mycobacterium tuberculosis, pubmed-meshheading:18977269-T-Lymphocytes, pubmed-meshheading:18977269-Tuberculosis
pubmed:year
2009
pubmed:articleTitle
Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
pubmed:affiliation
Institut Pasteur, Unité de Génétique Mycobactérienne, 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't